AML Clinical Trials

Here you will find articles that keep you up to date on the newest AML research that AML experts are recruiting for. AML research studies called clinical trials are all about drug development. Drugs must go through many phases of testing to receive FDA approval in order to be prescribed to patients by doctors. Joining a clinical trial for your AML has the potential to provide you with cutting-edge treatment that is not yet widely available to the general public.

In addition to drug development, AML research aims to answer important questions like "what is AML?", "what causes AML?", "is AML genetic?" and "how do we improve AML survival?"

There are over 300 AML research trials actively recruiting patients, which is more than any other leukemia. These articles will keep you informed on the latest clinical trials that are recruiting and the types of new drug therapies that are being studied for the treatment of AML.

Cancer Vaccine Being Studied as a New AML Maintenance Therapy

AML Clinical Trials—May 25, 2022

This update provides the first clear signal that MRD responses following DCP-001 vaccination translate into relevant survival benefits for AML patients.

Oral Hypomethylating Agent Can Provide an At-Home Treatment Option for AML

AML Clinical Trials—May 19, 2022

Clinical trial results are in for new drug that provides a treatment option for adult patients that can potentially reduce the number of doctor office visits.

HM43239 Treats Relapsed and Refractory AML

AML Clinical Trials—May 9, 2022

HM43239 has delivered complete remissions in a broad diversity of relapsed or refractory AML patients in an ongoing phase 1/2 clinical trial, including patients with prior failure of other FLT3 inhibitor agents.

AML Clinical Trial Update: PRGN-3006 and Magrolimab

AML Clinical Trials—April 18, 2022

Lisa Foster, HealthTree for AML Contributor, provides us an update on two important AML clinical trials looking at immnotherapy options for relapsed/refractory and TP53 positive AML.

Uproleselan Added to Chemotherapy is Showing Promise

AML Clinical Trials—March 21, 2022

A new drug called Uproleselan added to chemotherapy appears to increases the sensitivity of AML blasts to chemotherapy and improve response rates. This combination has the added benefit of potentially reducing the risk of mucositis. Further study results are hoped to be reported by the end of 2022 to determine if Uproleselan can become a major contributor in the treatment of AML.

A New AML Chemo Drug in Development with Less Heart Complications and Minimal Hair Loss

AML Clinical Trials—March 1, 2022

Annamycin is a new chemotherapy drug with potential in relapsed/refractory AML. It's perks when compared to the currently used chemotherapy include less risk for heart complications and the added benefit of minimal hair loss. This drug is currently in clinical trials and has recently received fast track designation from the FDA.

Targeting Bone Cells to Stop AML

AML Clinical Trials—February 11, 2022

An experimental drug called epacadostat targets bone forming cells called osteoblasts and has shown to block the progression of leukemia cells in mouse studies. Researchers hypothesize that by blocking leukemia cells and osteoblasts from communicating, we might be able to stop AML.

ASH 2021: A Drug to Finally Benefit Patients with TP53 Mutant AML?

AML Clinical Trials—January 20, 2022

At the 2021 ASH conference, Dr. Sallman from Moffitt Cancer Center in Florida presents his abstract on the long-term follow-up of Eprenetapopt (APR-246) for p53 mutant MDS and AML patients with ≤ 30% blasts. He hypothesizes that with this new therapy, patients may be able to get treatment pre and post-transplant which could finally lead to improved outcomes and potentially a cure for this difficult-to-treat subset of patients.

ASH 2021: An All Oral Combo for Newly Diagnosed Older Adults with Acute Myeloid Leukemia with Gabriel Mannis, MD

AML Clinical Trials—January 19, 2022

Dr. Mannis describes the oral abstact that he presented at the ASH 2021 annual meeting revealing that a new oral decitabine medication combined with another oral medication called venetoclax appears safe, well tolerated and just as effective as IV decitabine. It is Dr. Mannis's hope that this drug combination will become FDA approved in the near future and become the new standard of care for treating older adults with acute myeloid leukemia.

ASH 2021: Venetoclax Plus Decitabine for Young Adults with Adverse-Risk AML

AML Clinical Trials—January 13, 2022

Dr. Chen reports on his research at ASH which found that preliminary results indicate venetoclax plus decitabine is an effective, lower-intensity regimen that is well tolerated for young adults with newly diagnosed adverse-risk AML, producing high rates of complete response, low rates of infections, and low rates of early death.